Literature DB >> 8882596

Functional effects of econazole on inducible nitric oxide synthase: production of a calmodulin-dependent enzyme.

R G Bogle1, P Vallance.   

Abstract

1. We performed experiments to examine the effects of an anti-fungal imidazole compound, econazole, on the regulation and effects of lipopolysaccharide-inducible nitric oxide synthase (iNOS) activity in rat aortic rings and cultured J774 murine macrophage cells. 2. In endothelium-intact rings of thoracic aorta, phenylephrine caused a concentration-dependent contraction with EC50 of 1.9 +/- 0.15 x 10(-8) M (n = 5). Following incubation with lipopolysaccharide (LPS, 5 micrograms ml-1) for 8 h there was a right-shift in the concentration-response curve (EC50 3.1 +/- 0.28 x 10(-7) M, P < 0.05) with a depression in the maximum contraction from 1.44 +/- 0.25 g to 0.86 +/- 0.26 g (n = 4). Co-incubation of rings with econazole (1 x 10(-5) M) partially inhibited the LPS-induced loss of reactivity to phenylephrine (EC50 6.5 +/- 0.72 x 10(-8) M) and fully inhibited the reduction in maximum tension (1.49 +/- 0.19 g; n = 5). 3. In J774 cells, incubation with LPS (10 micrograms ml-1, 24 h) resulted in significant nitrite production that was inhibited by co-incubation with econazole (IC50 5.0 +/- 0.9 x 10(-6) M; n = 5). In cells stimulated with LPS, production of L-[3H]-citrulline from L-[3H]-arginine was 6.41 +/- 0.22 pmol mg-1 protein min-1 (n = 3). This was inhibited by 92 +/- 6% by addition of NG-monomethyl-L-arginine (L-NMMA, 1 x 10(-3) M; n = 3) to the homogenate but not by econazole (1 x 10(-5) M; n = 3). In contrast pretreatment of cells with econazole (1 x 10(-5) M) markedly reduced the LPS-induced [3H]-citrulline production (0.86 +/- 0.053 pmol mg-1 protein min-1; P < 0.01; n = 3). 4. In cells treated with LPS and econazole, L-[3H]-citrulline production was restored in a concentration-dependent manner by addition of calmodulin (1 x 10(-8)-3 x 10(-7) M) with an IC50 of 4.2 +/- 0.9 x 10(-8) M. 5. We have shown that econazole inhibits the functional and biochemical activity of iNOS in rat aortic rings and cultured J774 cells. Treatment of cells with econazole renders the NO synthase functionally inactive. In econazole-treated cells enzyme activity is restored by calmodulin suggesting that econazole may inhibit the binding of this essential co-factor to the enzyme following its production. These studies may have implications for the design of novel anti-inflammatory agents working through the L-arginine-nitric oxide pathway.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8882596      PMCID: PMC1909780          DOI: 10.1111/j.1476-5381.1996.tb16696.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  25 in total

1.  Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase.

Authors:  D S Bredt; P M Hwang; C E Glatt; C Lowenstein; R R Reed; S H Snyder
Journal:  Nature       Date:  1991-06-27       Impact factor: 49.962

2.  Purification and characterization of the cytokine-induced macrophage nitric oxide synthase: an FAD- and FMN-containing flavoprotein.

Authors:  D J Stuehr; H J Cho; N S Kwon; M F Weise; C F Nathan
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

Review 3.  Nitric oxide: physiology, pathophysiology, and pharmacology.

Authors:  S Moncada; R M Palmer; E A Higgs
Journal:  Pharmacol Rev       Date:  1991-06       Impact factor: 25.468

4.  L-arginine transport is increased in macrophages generating nitric oxide.

Authors:  R G Bogle; A R Baydoun; J D Pearson; S Moncada; G E Mann
Journal:  Biochem J       Date:  1992-05-15       Impact factor: 3.857

5.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

6.  Widespread tissue distribution, species distribution and changes in activity of Ca(2+)-dependent and Ca(2+)-independent nitric oxide synthases.

Authors:  M Salter; R G Knowles; S Moncada
Journal:  FEBS Lett       Date:  1991-10-07       Impact factor: 4.124

7.  Ketoconazole inhibits alveolar macrophage production of inflammatory mediators involved in acute lung injury (adult respiratory distress syndrome).

Authors:  J G Williams; R V Maier
Journal:  Surgery       Date:  1992-08       Impact factor: 3.982

8.  Ketoconazole prevents acute respiratory failure in critically ill surgical patients.

Authors:  G J Slotman; K W Burchard; A D'Arezzo; D S Gann
Journal:  J Trauma       Date:  1988-05

9.  Characterization of the effects of two new arginine/citrulline analogues on constitutive and inducible nitric oxide synthases in rat aorta.

Authors:  G A Joly; K Narayanan; O W Griffith; R G Kilbourn
Journal:  Br J Pharmacol       Date:  1995-06       Impact factor: 8.739

10.  Calmodulin is a subunit of nitric oxide synthase from macrophages.

Authors:  H J Cho; Q W Xie; J Calaycay; R A Mumford; K M Swiderek; T D Lee; C Nathan
Journal:  J Exp Med       Date:  1992-08-01       Impact factor: 14.307

View more
  3 in total

1.  Inhibition of inducible nitric oxide synthase by beta-lapachone in rat alveolar macrophages and aorta.

Authors:  S H Liu; H P Tzeng; M L Kuo; S Y Lin-Shiau
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 9.473

2.  Exploring the Role of CYP3A4 Mediated Drug Metabolism in the Pharmacological Modulation of Nitric Oxide Production.

Authors:  José Pérez-Del Palacio; Caridad Díaz; Noemí Vergara; Francesca Algieri; Alba Rodríguez-Nogales; Nuria de Pedro; M Elena Rodríguez-Cabezas; Olga Genilloud; Julio Gálvez; Francisca Vicente
Journal:  Front Pharmacol       Date:  2017-04-12       Impact factor: 5.810

3.  Econazole Induces p53-Dependent Apoptosis and Decreases Metastasis Ability in Gastric Cancer Cells.

Authors:  Eun Kyoung Choi; Eun Jung Park; Tien Thuy Phan; Hea Dong Kim; Kwang-Lae Hoe; Dong-Uk Kim
Journal:  Biomol Ther (Seoul)       Date:  2020-07-01       Impact factor: 4.634

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.